X4 Pharmaceuticals
XFOR
40 hedge funds and large institutions have $14.9M invested in X4 Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
14% more funds holding
Funds holding: 35 → 40 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7.75% less ownership
Funds ownership: 71.96% → 64.22% (-7.7%)
90% less capital inflows, than outflows
Capital inflows: $1.32M | Capital outflows: $12.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$296K |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$287K |
| 3 |
State Street
Boston,
Massachusetts
|
+$145K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$117K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alphabet Inc
Mountain View,
California
|
-$9.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.61M |
| 3 |
JP Morgan Chase
New York
|
-$168K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$32.7K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$2.54K |
XFOR Hedge Fund Activity: Q3 2018 in Review
40 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2018, worth a combined $14.9M — down 67% from $45.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XFOR positions and 2 closed out — a net gain of 5 holders — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Citigroup, adding an estimated $296K. The largest seller was Alphabet Inc, exiting entirely with an estimated $9.8M sold.
- 40 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2018, up from 35 in Q2 2018.
- Funds reported $14.9M of X4 Pharmaceuticals stock for Q3 2018, down 67% quarter-over-quarter.
- 7 funds opened new X4 Pharmaceuticals positions in Q3 2018 and 2 closed out, a net change of +5 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2018 was Citigroup, an estimated $296K added.
- The largest X4 Pharmaceuticals seller in Q3 2018 was Alphabet Inc, an estimated $9.8M sold.
Based on aggregated 13F filings for Q3 2018.